| __timestamp | Amphastar Pharmaceuticals, Inc. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 59644696 |
| Thursday, January 1, 2015 | 46974000 | 79541000 |
| Friday, January 1, 2016 | 47298000 | 98015000 |
| Sunday, January 1, 2017 | 50918000 | 103958000 |
| Monday, January 1, 2018 | 58044000 | 103654000 |
| Tuesday, January 1, 2019 | 63109000 | 128951000 |
| Wednesday, January 1, 2020 | 65157000 | 135799000 |
| Friday, January 1, 2021 | 68920000 | 149883000 |
| Saturday, January 1, 2022 | 66592000 | 220206000 |
| Sunday, January 1, 2023 | 80393000 | 265542000 |
Cracking the code
In the competitive world of biopharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc. offer a fascinating case study in SG&A efficiency from 2014 to 2023. Over this period, Amphastar's SG&A expenses grew by approximately 99%, while Travere's surged by an impressive 345%. This stark contrast highlights differing strategic priorities and operational efficiencies. Amphastar maintained a more conservative growth in expenses, suggesting a focus on cost control. In contrast, Travere's significant increase in SG&A spending could indicate aggressive expansion or investment in administrative capabilities. As of 2023, Travere's SG&A expenses were more than three times those of Amphastar, reflecting its larger scale or different business model. Understanding these trends provides valuable insights into each company's strategic direction and operational focus.
Selling, General, and Administrative Costs: argenx SE vs Amphastar Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Biogen Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BeiGene, Ltd. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Neurocrine Biosciences, Inc. vs Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
Amphastar Pharmaceuticals, Inc. or Travere Therapeutics, Inc.: Who Leads in Yearly Revenue?
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.